Inactivation of the mTORC1-Eukaryotic Translation Initiation Factor 4E Pathway Alters Stress Granule Formation

REFERENCES

• Moeller BJ, Cao Y, Li CY, Dewhirst MW. 2004. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5:429–441.
   PubMed Web of Science ®Google Scholar
• Gardner LB. 2008. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response. Mol. Cell. Biol. 28:3729–3741.
   PubMed Web of Science ®Google Scholar
• Mazroui R, Sukarieh R, Bordeleau ME, Kaufman RJ, Northcote P, Tanaka J, Gallouzi I, Pelletier J. 2006. Inhibition of ribosome recruitment induces stress granule formation independently of eukaryotic initiation factor 2alpha phosphorylation. Mol. Biol. Cell 17:4212–4219.
   PubMedGoogle Scholar
• McInerney GM, Kedersha NL, Kaufman RJ, Anderson P, Liljestrom P. 2005. Importance of eIF2alpha phosphorylation and stress granule assembly in alphavirus translation regulation. Mol. Biol. Cell 16:3753–3763.
   PubMedGoogle Scholar
• Fournier MJ, Gareau C, Mazroui R. 2010. The chemotherapeutic agent bortezomib induces the formation of stress granules. Cancer Cell Int. 10:12. doi:10.1186/1475-2867-10-12.
   PubMedGoogle Scholar
• Gareau C, Fournier MJ, Filion C, Coudert L, Martel D, Labelle Y, Mazroui R. 2011. p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis. PLoS One 6:e20254. doi:10.1371/journal.pone.0020254.
   PubMedGoogle Scholar
• Mazroui R, Di Marco S, Kaufman RJ, Gallouzi IE. 2007. Inhibition of the ubiquitin-proteasome system induces stress granule formation. Mol. Biol. Cell 18:2603–2618.
   PubMed Web of Science ®Google Scholar
• Anderson P, Kedersha N. 2006. RNA granules. J. Cell Biol. 172:803–808.
   PubMed Web of Science ®Google Scholar
• Anderson P, Kedersha N. 2008. Stress granules: the Tao of RNA triage. Trends Biochem. Sci. 33:141–150.
   PubMed Web of Science ®Google Scholar
• Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito H, Takekawa M. 2008. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat. Cell Biol. 10:1324–1332.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Back SH, Kim V, Ryu I, Jang SK. 2005. Sequestration of TRAF2 into stress granules interrupts tumor necrosis factor signaling under stress conditions. Mol. Cell. Biol. 25:2450–2462.
   PubMedGoogle Scholar
• Morita T, Satoh R, Umeda N, Kita A, Sugiura R. 2012. The stress granule protein Vgl1 and poly(A)-binding protein Pab1 are required for doxorubicin resistance in the fission yeast Schizosaccharomyces pombe. Biochem. Biophys. Res. Commun. 417:399–403.
   PubMedGoogle Scholar
• McConkey DJ, Zhu K. 2008. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 11:164–179.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. 2008. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev. Anticancer Ther. 8:1053–1072.
   PubMed Web of Science ®Google Scholar
• Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O. 2008. The potential of proteasome inhibitors in cancer therapy. Expert Opin. Invest. Drugs 17:879–895.
   PubMed Web of Science ®Google Scholar
• Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. 2006. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat. Clin. Pract. Oncol. 3:374–387.
   PubMedGoogle Scholar
• Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J. 2006. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol. Cancer Ther. 5:665–675.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. 2009. The pharmacology of mTOR inhibition. Sci. Signal. 2:pe24. doi:10.1126/scisignal.267pe24.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274–293.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6:1122–1128.
   PubMed Web of Science ®Google Scholar
• Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM. 2009. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137:873–886.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296–1302.
   PubMed Web of Science ®Google Scholar
• Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T. 2006. Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J. Biol. Chem. 281:28605–28614.
   PubMed Web of Science ®Google Scholar
• Wang L, Rhodes CJ, Lawrence JCJr. 2006. Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J. Biol. Chem. 281:24293–24303.
   PubMed Web of Science ®Google Scholar
• Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. 2010. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol. Cell 38:768–774.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. 2006. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol. Cell 24:185–197.
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K. 2002. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110:177–189.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163–175.
   PubMed Web of Science ®Google Scholar
• Zhou H, Huang S. 2010. The complexes of mammalian target of rapamycin. Curr. Protein Pept. Sci. 11:409–424.
   PubMed Web of Science ®Google Scholar
• Richter JD, Sonenberg N. 2005. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477–480.
   PubMed Web of Science ®Google Scholar
• Sonenberg N. 2008. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem. Cell Biol. 86:178–183.
   PubMedGoogle Scholar
• Haghighat A, Sonenberg N. 1997. eIF4G dramatically enhances the binding of eIF4E to the mRNA 5′-cap structure. J. Biol. Chem. 272:21677–21680.
   PubMedGoogle Scholar
• Haghighat A, Svitkin Y, Novoa I, Kuechler E, Skern T, Sonenberg N. 1996. The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase. J. Virol. 70:8444–8450.
   PubMed Web of Science ®Google Scholar
• Haghighat A, Mader S, Pause A, Sonenberg N. 1995. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 14:5701–5709.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, Aebersold R, Sonenberg N. 1999. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13:1422–1437.
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. 2004. eIF4E—from translation to transformation. Oncogene 23:3172–3179.
   PubMed Web of Science ®Google Scholar
• Rong L, Livingstone M, Sukarieh R, Petroulakis E, Gingras AC, Crosby K, Smith B, Polakiewicz RD, Pelletier J, Ferraiuolo MA, Sonenberg N. 2008. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 14:1318–1327.
   PubMedGoogle Scholar
• Rousseau D, Gingras AC, Pause A, Sonenberg N. 1996. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415–2420.
   PubMedGoogle Scholar
• Averous J, Proud CG. 2006. When translation meets transformation: the mTOR story. Oncogene 25:6423–6435.
   PubMed Web of Science ®Google Scholar
• Huang S, Houghton PJ. 2003. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3:371–377.
   PubMed Web of Science ®Google Scholar
• Janus A, Robak T, Smolewski P. 2005. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell. Mol. Biol. Lett. 10:479–498.
   PubMed Web of Science ®Google Scholar
• Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. 2006. mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 94:195–199.
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Carter JH, Marcusson EG. 2008. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68:631–634.
   PubMed Web of Science ®Google Scholar
• Graff JR, Konicek BW, Vincent TM, Lynch RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS, Chen Y, Zhang H, Sissons S, Cox K, McNulty AM, Parsons SH, Wang T, Sams L, Geeganage S, Douglass LE, Neubauer BL, Dean NM, Blanchard K, Shou J, Stancato LF, Carter JH, Marcusson EG. 2007. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 117:2638–2648.
   PubMed Web of Science ®Google Scholar
• Konicek BW, Dumstorf CA, Graff JR. 2008. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 7:2466–2471.
   PubMed Web of Science ®Google Scholar
• Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. 2006. mTOR, translation initiation and cancer. Oncogene 25:6416–6422.
   PubMed Web of Science ®Google Scholar
• Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, Glass J, Agarwal A, Caldito G. 2007. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res. 67:2160–2168.
   PubMed Web of Science ®Google Scholar
• Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. 2009. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7:e38. doi:10.1371/journal.pbio.1000038.
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. 2009. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284:8023–8032.
   PubMed Web of Science ®Google Scholar
• Grosso S, Pesce E, Brina D, Beugnet A, Loreni F, Biffo S. 2011. Sensitivity of global translation to mTOR inhibition in REN cells depends on the equilibrium between eIF4E and 4E-BP1. PLoS One 6:e29136. doi:10.1371/journal.pone.0029136.
   PubMedGoogle Scholar
• Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. 2010. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17:249–261.
   PubMed Web of Science ®Google Scholar
• Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. 2012. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485:109–113.
   PubMed Web of Science ®Google Scholar
• Mokas S, Mills JR, Garreau C, Fournier MJ, Robert F, Arya P, Kaufman RJ, Pelletier J, Mazroui R. 2009. Uncoupling stress granule assembly and translation initiation inhibition. Mol. Biol. Cell 20:2673–2683.
   PubMed Web of Science ®Google Scholar
• Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA. 2012. Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget 3:869–881.
   PubMed Web of Science ®Google Scholar
• Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA, Wagner G. 2007. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128:257–267.
   PubMed Web of Science ®Google Scholar
• Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW. 2002. Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. Hum. Mol. Genet. 11:3007–3017.
   PubMed Web of Science ®Google Scholar
• Tourrière H, Chebli K, Zekri L, Courselaud B, Blanchard JM, Bertrand E, Tazi J. 2003. The RasGAP-associated endoribonuclease G3BP assembles stress granules. J. Cell Biol. 160:823–831.
   PubMed Web of Science ®Google Scholar
• Kedersha N, Chen S, Gilks N, Li W, Miller IJ, Stahl J, Anderson P. 2002. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Mol. Biol. Cell 13:195–210.
   PubMed Web of Science ®Google Scholar
• Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N, Golan DE, Anderson P. 2000. Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. J. Cell Biol. 151:1257–1268.
   PubMed Web of Science ®Google Scholar
• Kedersha NL, Gupta M, Li W, Miller I, Anderson P. 1999. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J. Cell Biol. 147:1431–1442.
   PubMed Web of Science ®Google Scholar
• McEwen E, Kedersha N, Song B, Scheuner D, Gilks N, Han A, Chen JJ, Anderson P, Kaufman RJ. 2005. Heme-regulated inhibitor kinase-mediated phosphorylation of eukaryotic translation initiation factor 2 inhibits translation, induces stress granule formation, and mediates survival upon arsenite exposure. J. Biol. Chem. 280:16925–16933.
   PubMed Web of Science ®Google Scholar
• Holcik M, Sonenberg N. 2005. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 6:318–327.
   PubMed Web of Science ®Google Scholar
• Wippich F, Bodenmiller B, Trajkovska MG, Wanka S, Aebersold R, Pelkmans L. 2013. Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell 152:791–805.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. 2010. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta 1804:433–439.
   PubMed Web of Science ®Google Scholar
• Sukarieh R, Sonenberg N, Pelletier J. 2009. The eIF4E-binding proteins are modifiers of cytoplasmic eIF4E relocalization during the heat shock response. Am. J. Physiol. Cell Physiol. 296:C1207–C1217.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, Wang X, Larsson O, Selvaraj A, Liu Y, Kozma SC, Thomas G, Sonenberg N. 2010. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328:1172–1176.
   PubMed Web of Science ®Google Scholar
• Patel J, McLeod LE, Vries RG, Flynn A, Wang X, Proud CG. 2002. Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur. J. Biochem. 269:3076–3085.
   PubMedGoogle Scholar
• Wu XN, Wang XK, Wu SQ, Lu J, Zheng M, Wang YH, Zhou H, Zhang H, Han J. 2011. Phosphorylation of Raptor by p38beta participates in arsenite-induced mammalian target of rapamycin complex 1 (mTORC1) activation. J. Biol. Chem. 286:31501–31511.
   PubMedGoogle Scholar
• Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, Zammit D, Marcus V, Metrakos P, Voyer LA, Gandin V, Liu Y, Topisirovic I, Sonenberg N. 2012. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 72:6468–6476.
   PubMed Web of Science ®Google Scholar
• Lin TA, Kong X, Haystead TA, Pause A, Belsham G, Sonenberg N, Lawrence JCJr. 1994. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science 266:653–656.
   PubMed Web of Science ®Google Scholar
• Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JCJr, Sonenberg N. 1994. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371:762–767.
   PubMed Web of Science ®Google Scholar
• Poulin F, Gingras AC, Olsen H, Chevalier S, Sonenberg N. 1998. 4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family. J. Biol. Chem. 273:14002–14007.
   PubMed Web of Science ®Google Scholar
• Buchan JR, Parker R. 2009. Eukaryotic stress granules: the ins and outs of translation. Mol. Cell 36:932–941.
   PubMed Web of Science ®Google Scholar
• Bragado P, Estrada Y, Sosa MS, Avivar-Valderas A, Cannan D, Genden E, Teng M, Ranganathan AC, Wen HC, Kapoor A, Bernstein E, Aguirre-Ghiso JA. 2012. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS One 7:e29974. doi:10.1371/journal.pone.0029974.
   PubMedGoogle Scholar
• Gloesenkamp CR, Nitzsche B, Ocker M, Di Fazio P, Quint K, Hoffmann B, Scherubl H, Hopfner M. 2012. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int. J. Oncol. 40:876–888.
   PubMedGoogle Scholar
• Petitclerc E, Deschesnes RG, Cote MF, Marquis C, Janvier R, Lacroix J, Miot-Noirault E, Legault J, Mounetou E, Madelmont JC, C-Gaudreault R. 2004. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance. Cancer Res. 64:4654–4663.
   PubMedGoogle Scholar
• Ribatti D, Nico B, Cimpean AM, Raica M, Crivellato E, Ruggieri S, Vacca A. 19 April 2012. B16-F10 melanoma cells contribute to the new formation of blood vessels in the chick embryo chorioallantoic membrane through vasculogenic mimicry. Clin. Exp. Med. [Epub ahead of print.]
   Google Scholar
• Fujimura K, Sasaki AT, Anderson P. 2012. Selenite targets eIF4E-binding protein-1 to inhibit translation initiation and induce the assembly of non-canonical stress granules. Nucleic Acids Res. 40:8099–8110.
   PubMedGoogle Scholar
• Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. 2012. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55–61.
   PubMed Web of Science ®Google Scholar
• Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, Sonenberg N. 2012. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl. Acad. Sci. U. S. A. 109:8977–8982.
   PubMed Web of Science ®Google Scholar
• Hilliker A, Gao Z, Jankowsky E, Parker R. 2011. The DEAD-box protein Ded1 modulates translation by the formation and resolution of an eIF4F-mRNA complex. Mol. Cell 43:962–972.
   PubMed Web of Science ®Google Scholar
• Rajyaguru P, She M, Parker R. 2012. Scd6 targets eIF4G to repress translation: RGG motif proteins as a class of eIF4G-binding proteins. Mol. Cell 45:244–254.
   PubMed Web of Science ®Google Scholar
• Shih JW, Wang WT, Tsai TY, Kuo CY, Li HK, Wu Lee YH. 2012. Critical roles of RNA helicase DDX3 and its interactions with eIF4E/PABP1 in stress granule assembly and stress response. Biochem. J. 441:119–129.
   PubMed Web of Science ®Google Scholar
• Svitkin YV, Herdy B, Costa-Mattioli M, Gingras AC, Raught B, Sonenberg N. 2005. Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol. Cell. Biol. 25:10556–10565.
   PubMed Web of Science ®Google Scholar
• Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc P, Imataka H, Mikami S, Martineau Y, Ronai ZA, Sonenberg N. 2012. Translational homeostasis via the mRNA cap-binding protein, eIF4E. Mol. Cell 46:847–858.
   PubMed Web of Science ®Google Scholar
• Di Marco S, Hel Z, Lachance C, Furneaux H, Radzioch D. 2001. Polymorphism in the 3′-untranslated region of TNFalpha mRNA impairs binding of the posttranscriptional regulatory protein HuR to TNFalpha mRNA. Nucleic Acids Res. 29:863–871.
   PubMed Web of Science ®Google Scholar